E-cigarettes and HIV: The Overlooked Population That Could Benefit Most From Harm Reduction

In the era of effective antiretroviral therapy, the leading cause of death among people living with HIV in high-income countries is no longer opportunistic infections. It's smoking-related disease. Cardiovascular disease, lung cancer, and COPD now kill more HIV-positive individuals than AIDS-related conditions. The statistics are stark: people with HIV lose more years of life to smoking than to the virus itself, and a 35-year-old HIV-positive smoker has a life expectancy 8–10 years shorter than an HIV-positive non-smoker, a gap that's larger than the mortality reduction achieved by modern antiretroviral therapy. The convergence of the HIV and tobacco epidemics has created a population for whom smoking cessation is as medically urgent as viral suppression—and for whom conventional cessation approaches have been largely ineffective. This is the population that could benefit most dramatically from tobacco harm reduction, and it's been almost entirely overlooked in the policy debate.

The smoking rate among people living with HIV is two to three times the general population rate—roughly 40–50% in most cohorts compared to 10–15% in the general population. The elevated rate reflects the intersection of multiple risk factors: higher prevalence of mental health conditions (depression, anxiety, PTSD), higher rates of substance use, higher exposure to socioeconomic stressors (poverty, housing instability), and the historical concentration of HIV in communities—LGBTQ+ populations, people who inject drugs, communities of color—that also have elevated smoking rates. Smoking in this population is not a simple 'bad habit' that can be addressed with generic cessation messaging. It's embedded in a complex matrix of medical, psychological, and social factors that require tailored, intensive interventions. The standard cessation approaches—brief physician advice, quitlines, NRT—have produced disappointing results in HIV cohorts, with quit rates substantially lower than in the general population.

The clinical case for harm reduction in this population is particularly strong. People with HIV who smoke face a 'double hit' to their cardiovascular and pulmonary systems: the chronic inflammation from HIV (even when virally suppressed, residual immune activation persists) combined with the direct toxicity of tobacco smoke. The interaction is more than additive—HIV and smoking synergistically increase the risk of cardiovascular events, certain cancers (particularly lung and anal cancer), and COPD. Switching from cigarettes to a non-combustible nicotine product would eliminate the combustion-related toxicity while preserving the nicotine that many HIV-positive smokers use to manage stress, depression, and the side effects of antiretroviral medications. For a population that's already managed to adhere to a daily medication regimen (antiretroviral therapy), transitioning to a different nicotine delivery system is behaviorally more feasible than complete abstinence, which requires surrendering a coping mechanism that serves multiple functions.

Several pilot studies have explored vaping as a harm-reduction intervention for HIV-positive smokers, with results that are preliminary but promising. A 2023 feasibility trial at a major HIV clinic provided e-cigarettes and brief counseling to HIV-positive smokers who had previously failed to quit with conventional methods. At six months, 35% had switched completely to vaping, and an additional 25% had reduced their cigarette consumption by more than half. The participants reported that vaping addressed the stress and mood management functions that had made quitting so difficult in the past, while eliminating the stigma of smelling like smoke (a significant concern for a population that already navigates HIV-related stigma). The study was small and uncontrolled, but it demonstrated the principle: for a population with refractory smoking and a high burden of smoking-related disease, harm reduction achieved what abstinence-focused approaches had not.

The intersection of HIV and smoking also illuminates a broader issue in harm reduction: the populations that stand to benefit most from safer nicotine products are precisely the populations that are least well-served by the healthcare system and most vulnerable to industry exploitation. The same structural factors that produced elevated HIV rates in marginalized communities—racism, poverty, inadequate healthcare access, criminalization—also produced elevated smoking rates. Offering these communities safer nicotine products without addressing the structural determinants that drive nicotine use, and without robust regulatory protections against industry targeting, would be an incomplete and potentially exploitative intervention. A comprehensive approach would pair harm reduction with structural interventions: integrating smoking cessation and harm reduction into HIV care, making safer nicotine products affordable and accessible through the same channels that deliver antiretroviral therapy, and ensuring that the tobacco industry—which has a documented history of targeting LGBTQ+ communities—is excluded from the design and implementation of these programs.

The global dimension is particularly urgent. The burden of HIV and the burden of smoking are both shifting toward low- and middle-income countries, particularly in sub-Saharan Africa, where HIV prevalence remains high and the tobacco industry is aggressively expanding its market. The intersection of these two epidemics in settings with limited healthcare infrastructure is a looming public health catastrophe that's receiving almost no attention. As antiretroviral therapy becomes more widely available and people with HIV in LMICs live longer, smoking-related disease will emerge as a major cause of mortality that health systems are unprepared to address. Integrating tobacco harm reduction into HIV care in these settings—through affordable cessation pharmacotherapy, harm-reduction counseling, and access to lower-risk nicotine products—could prevent a wave of smoking-related deaths that would otherwise follow the wave of AIDS-related deaths that treatment access has begun to reduce.

The relative neglect of smoking in HIV care reflects a broader failure to integrate addiction treatment into the management of chronic diseases where addiction is a major driver of mortality. People with HIV who smoke are not outliers. They're representative of a pattern that recurs across chronic disease populations—people with mental illness, people with substance use disorders, people with diabetes and cardiovascular disease—where smoking cessation is as important to long-term survival as the primary disease management, but receives a fraction of the attention and resources. The HIV experience demonstrates both the urgency of addressing smoking in medically vulnerable populations and the potential of harm-reduction approaches to reach patients who've been failed by abstinence-only frameworks. The lesson extends beyond HIV. The populations that need harm reduction most are the populations that the healthcare system has historically treated last.